Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 14.01 | 11.67 | 9.86 | 13.19 | 9.35 | 8.26 | 10.22 | 3.52 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +41.3% | -3.6% | +274.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.36 | 20.13 | 6.68 | 5.25 | 3.20 | 1.65 | 1.58 | 1.83 | 4.01 | 3.83 | 3.54 | 2.80 | 1.64 | 1.61 | 2.12 | 2.00 | 2.18 | 2.72 | 2.25 | 1.84 | 2.33 |
| — | +1116.6% | +321.8% | +186.3% | -20.2% | -56.8% | -55.3% | -34.5% | +144.7% | +138.3% | +67.4% | +39.9% | -24.8% | -40.9% | -5.9% | +8.8% | -6.5% | +9.9% | -29.6% | -41.5% | -58.7% | |
| P/FCF | — | — | — | 1.99 | — | — | — | 0.71 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | +181.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.9% | 98.8% | 96.6% | 100.0% | 84.5% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -1.2% | -3.4% | 0.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -449.9% | -349.8% | -431.5% | -497.6% | -385.5% | -475.3% | -458.6% | -41.7% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +26.4% | +5.9% | -1094.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -412.9% | -327.3% | -401.5% | -467.2% | -357.2% | -432.5% | -407.1% | -35.7% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +24.3% | +1.4% | -1210.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -94.8% | -87.4% | -52.0% | -38.9% | -27.0% | -19.7% | -14.8% | -4.6% | -12.2% | -10.5% | -11.0% | -10.3% | -8.7% | -8.7% | -8.4% | -7.9% | -8.2% | -7.5% | -6.6% | -6.3% | -6.1% |
| — | -342.8% | -252.3% | -747.1% | -121.2% | -88.6% | -34.5% | +55.6% | -40.9% | -20.4% | -31.4% | -31.2% | -6.2% | -15.8% | -26.5% | -25.3% | -33.7% | -27.7% | -28.8% | -10.4% | +19.2% | |
| ROA | -37.2% | -11.0% | -10.5% | -11.7% | -11.1% | -9.3% | -7.6% | -3.1% | -10.9% | -9.5% | -9.9% | -9.3% | -8.0% | -8.1% | -7.7% | -7.3% | -7.7% | -7.2% | -6.3% | -6.0% | -5.8% |
| — | -18.8% | -38.1% | -276.3% | -1.7% | +2.5% | +22.7% | +66.6% | -37.3% | -17.8% | -27.9% | -26.6% | -3.2% | -12.6% | -22.9% | -22.5% | -32.6% | -28.3% | -29.8% | -12.8% | +15.2% | |
| ROIC | -181.3% | -114.4% | -85.3% | -61.0% | -29.3% | -18.9% | -18.0% | -5.6% | -10.8% | -9.2% | -9.5% | -8.8% | -7.6% | -7.5% | -7.2% | -7.4% | -7.3% | -6.1% | -5.6% | -5.4% | -4.9% |
| — | -504.1% | -373.2% | -980.2% | -170.1% | -105.5% | -89.3% | +36.0% | -43.3% | -23.7% | -32.7% | -19.8% | -3.4% | -21.6% | -27.2% | -37.3% | -48.9% | -23.3% | +3.9% | +26.0% | +39.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.50 | 0.22 | 0.12 | 0.08 | 0.06 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +692.1% | +323.6% | +192.8% | +104.5% | +77.5% | +58.1% | -7.3% | -3.2% | +26.5% | -1.9% | +29.8% | +215.9% | +116.5% | +155.4% | +145.9% | -6.9% | +8.7% | -43.0% | -44.6% | -72.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.06 | 4.73 | 6.15 | 6.06 | 5.12 | 6.16 | 8.07 | 9.46 | 11.47 | 14.94 | 16.67 | 12.26 | 16.71 | 20.32 | 21.65 | 18.56 | 17.64 | 25.73 | 27.48 | 23.26 | 25.03 |
| — | -23.1% | -23.8% | -36.0% | -55.4% | -58.8% | -51.6% | -22.8% | -31.3% | -26.5% | -23.0% | -33.9% | -5.3% | -21.0% | -21.2% | -20.2% | -29.6% | -4.5% | +13.1% | -5.0% | +65.2% | |
| Quick Ratio | 6.05 | 4.71 | 6.14 | 6.05 | 5.12 | 6.16 | 8.07 | 9.46 | 11.47 | 14.94 | 16.67 | 12.26 | 16.71 | 20.32 | 21.65 | 18.56 | 17.64 | 25.73 | 27.48 | 23.26 | 25.03 |
| — | -23.5% | -23.9% | -36.0% | -55.4% | -58.8% | -51.6% | -22.8% | -31.3% | -26.5% | -23.0% | -33.9% | -5.3% | -21.0% | -21.2% | -20.2% | -29.6% | -4.5% | +13.1% | -5.0% | +65.2% | |
| Interest Coverage | -183.11 | -197.03 | -217.23 | -232.90 | -188.59 | -168.11 | -150.75 | -41.68 | -131.05 | -124.21 | -123.43 | -107.59 | -94.55 | -95.06 | -92.60 | -143.60 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KURA stock.
Kura Oncology, Inc.'s current P/E is -3.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Kura Oncology, Inc.'s current operating margin is -449.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kura Oncology, Inc.'s business trajectory between earnings reports.